COMPASS Pathways, a mental health treatment business, been given the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute, a nonprofit health-related researcher, acquired the designation to continue its screening of psilocybin as being a treatment for important depressive disorder.Altman Before